CV
Univ. Prof. Dr. med. Michael Hölzel
Academic education
1996 - 2003: Medical School, Ludwig-Maximilians-University (LMU) Munich
Scientific degrees
6/2004: Medical thesis (Dr. med.), LMU Munich, Summa cum Laude: “Regulation von Teilungswahrscheinlichkeit und Zellzyklusdauer durch das Onkoprotein c-Myc” (Supervisor: Professor Dr. Dirk Eick Helmholtz-Research Center, Munich; Prof. Dr. Wolfram Hörz, Department of Biochemistry, LMU Munich)
3/2003: M.D., Graduation from Medical School, LMU Munich
Scientific career
2019: Appointed as W3 professor and director of the Institute of Experimental Oncology, University Hospital Bonn
2016: Head of liquid biobanking core facility, Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn
2012 - present: Appointment as W2 professor for RNA Biology, Institute for Clinical Chemistry and Clinical Pharmacology, University Hospital Bonn (Director Prof. Dr. G. Hartmann)
2007 - 2011: Postdoctoral fellow, The Netherlands Cancer Institute (NKI), Amsterdam, Department of Molecular Carcinogenesis (Group of Professor Rene Bernards, PhD)
2006: Postdoctoral fellow, Helmholtz-Research Center, Munich (Group of Professor Dr. Dirk Eick)
2003 - 2005: Residency in hematology/oncology, Department III for Internal Medicine, Klinikum Grosshadern, LMU Munich (Director Prof. Dr. W. Hiddemann)
Honors/ Awards/ Memberships
2016: Speaker of the BONFOR SciMed MD thesis program
2016 - 2018: Speaker of the Life Science Networking Program "Bonner Forum Biomedizin" (BfB)
2015: Speaker of Bonn NeuroImmunology (BonnNI), MD thesis program funded by the Else-Kröner-Fresenius Foundation
2012: Core member of the DFG excellence cluster ImmunoSensation
2001: Scholarship Harvard-Munich-Alliance (LMU, Munich)
1999: Scholarship Studienstiftung des deutschen Volkes
Contact Information
Univ. Prof. Dr. med. Michael Hölzel
Professor (W3)
University Hospital Bonn
Institute of Experimental Oncology
10 most relevant publications
- Giordano FA, Layer JP, Turiello R, Friker LL, Mirallas O, Pregler BEF, Potthoff AL, Zeyen T, Weller J, Sperk E, Sahm K, Oster C, Kebir S, Hambsch P, Schäfer N, Kadzik S, Renovanz M, Pietsch T, Bisdas S, Sepúlveda-Sánchez JM, Gómez-Puerto D, Vieito M, Platten M, Gkika E, Grauer OM, Tabatabai G, Schneider M, Glas M, Seidel C, Herrlinger U*, Hölzel M*. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy and bevacizumab in newly-diagnosed glioblastoma: expansion of the phase I/II GLORIA trial. Nat Commun. 2026;17(1):3405. doi:10.1038/s41467-026-71362-7 *shared senior authors
- Giordano FA, Layer JP, Leonardelli S, Friker LL, Turiello R, Corvino D, Zeyen T, Schaub C, Müller W, Sperk E, Schmeel LC, Sahm K, Oster C, Kebir S, Hambsch P, Pietsch T, Bisdas S, Platten M, Glas M, Seidel C, Herrlinger U*, Hölzel M*. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial. Nat Commun. 2024;15(1):4210. doi:10.1038/s41467-024-48416-9 *shared senior authors
- Bawden EG, Wagner T, Schröder J, Effern M, Hinze D, Newland L, Attrill GH, Lee AR, Engel S, Freestone D, de Lima Moreira M, Gressier E, McBain N, Bachem A, Haque A, Dong R, Ferguson AL, Edwards JJ, Ferguson PM, Scolyer RA, Wilmott JS, Jewell CM, Brooks AG, Gyorki DE, Palendira U, Bedoui S, Waithman J, Hochheiser K, Hölzel M*, Gebhardt T*. CD4 + T cell immunity against cutaneous melanoma encompasses multifaceted MHC II–dependent responses. Sci Immunol. 2024;9(91). doi:10.1126/sciimmunol.adi9517 *shared senior authors
- Seier JA, Reinhardt J, Saraf K, Ng SS, Layer JP, Corvino D, Althoff K, Giordano FA, Schramm A, Fischer M, Hölzel M. Druggable epigenetic suppression of interferon-induced chemokine expression linked to MYCN amplification in neuroblastoma. J Immunother Cancer. 2021;9(5):e001335. doi:10.1136/jitc-2020-001335
- Effern M, Glodde N, Braun M, Liebing J, Boll HN, Yong M, Bawden E, Hinze D, van den Boorn-Konijnenberg D, Daoud M, Aymans P, Landsberg J, Smyth MJ, Flatz L, Tüting T, Bald T, Gebhardt T, Hölzel M. Adoptive T Cell Therapy Targeting Different Gene Products Reveals Diverse and Context-Dependent Immune Evasion in Melanoma. Immunity. 2020;53(3):564-580.e9. doi:10.1016/j.immuni.2020.07.007
- Glodde N, Bald T, van den Boorn-Konijnenberg D, Nakamura K, O’Donnell JS, Szczepanski S, Brandes M, Eickhoff S, Das I, Shridhar N, Hinze D, Rogava M, van der Sluis TC, Ruotsalainen JJ, Gaffal E, Landsberg J, Ludwig KU, Wilhelm C, Riek-Burchardt M, Müller AJ, Gebhardt C, Scolyer RA, Long G v., Janzen V, Teng MWL, Kastenmüller W, Mazzone M, Smyth MJ, Tüting T*, Hölzel M*. Reactive Neutrophil Responses Dependent on the Receptor Tyrosine Kinase c-MET Limit Cancer Immunotherapy. Immunity. 2017;47(4):789-802.e9. doi:10.1016/j.immuni.2017.09.012 *shared senior authors
- Reinhardt J, Landsberg J, Schmid-Burgk JL, Ramis BB, Bald T, Glodde N, Lopez-Ramos D, Young A, Ngiow SF, Nettersheim D, Schorle H, Quast T, Kolanus W, Schadendorf D, Long G v., Madore J, Scolyer RA, Ribas A, Smyth MJ, Tumeh PC, Tüting T, Hölzel M. MAPK Signaling and Inflammation Link Melanoma Phenotype Switching to Induction of CD73 during Immunotherapy. Cancer Res. 2017;77(17):4697-4709. doi:10.1158/0008-5472.CAN-17-0395
- Hölzel M, Landsberg J, Glodde N, Bald T, Rogava M, Riesenberg S, Becker A, Jönsson G, Tüting T. A Preclinical Model of Malignant Peripheral Nerve Sheath Tumor-like Melanoma Is Characterized by Infiltrating Mast Cells. Cancer Res. 2016;76(2):251-263. doi:10.1158/0008-5472.CAN-15-1090
- Riesenberg S, Groetchen A, Siddaway R, Bald T, Reinhardt J, Smorra D, Kohlmeyer J, Renn M, Phung B, Aymans P, Schmidt T, Hornung V, Davidson I, Goding CR, Jönsson G, Landsberg J, Tüting T, Hölzel M. MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment. Nat Commun. 2015;6(1):8755. doi:10.1038/ncomms9755
- Bald T, Quast T, Landsberg J, Rogava M, Glodde N, Lopez-Ramos D, Kohlmeyer J, Riesenberg S, van den Boorn-Konijnenberg D, Hömig-Hölzel C, Reuten R, Schadow B, Weighardt H, Wenzel D, Helfrich I, Schadendorf D, Bloch W, Bianchi ME, Lugassy C, Barnhill RL, Koch M, Fleischmann BK, Förster I, Kastenmüller W, Kolanus W, Hölzel M*, Gaffal E*, Tüting T*. Ultraviolet-radiation-induced inflammation promotes angiotropism and metastasis in melanoma. Nature. 2014;507(7490):109-113. doi:10.1038/nature13111 *co-corresponding author
